Differential Effects of Drug-Eluting Stents on Local Endothelium-Dependent Coronary Vasomotion

Journal of the American College of Cardiology

Volumn 51, Issue 22, 2008, Pages 2123-2129

  Hamilos, Michalis I ^a   Ostojic, Miodrag ^b   Beleslin, Branko ^b   Sagic, Dragan ^c   Mangovski, Ljubco ^c   Stojkovic, Sinisa ^b   Nedeljkovic, Milan ^b   Orlic, Dejan ^b   Milosavljevic, Bratislav ^c   Topic, Dragan ^c   Karanovic, Nevena ^d   Wijns, William ^a  

^a CARDIOVASCULAR CENTER   (Belgium)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c Institute for Cardiovascular Disease Dedinje   (Serbia)

^d Institute of Public Health of Serbia   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC ACID DERIVATIVE; POLYMER; RAPAMYCIN;

ADULT; ANGIOCARDIOGRAPHY; ARTERY ENDOTHELIUM; ARTICLE; CARDIAC PATIENT; CLINICAL ARTICLE; CORONARY STENT; DRUG ELUTING STENT; DRUG RELEASE; FEMALE; HEART RATE; HUMAN; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINUS NODE; STATISTICAL SIGNIFICANCE; VASOCONSTRICTION; VASODILATATION;

CORONARY ANGIOGRAPHY; CORONARY VESSELS; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; FEMALE; HEMODYNAMICS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES; SIROLIMUS; VASOCONSTRICTION; VASODILATION;

EID: 44049101889     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.12.059     Document Type: Article

References (31)

1. Camenzind E., Steg P.G., and Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115 (2007) 1440-1455
2. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
3. Lagerqvist B., James S.K., Stenestrand U., and SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
4. Togni M., Raber L., Cocchia R., et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol 120 (2007) 212-220
5. Hofma S., Van der Giessen W., Van Dalen B., et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27 (2006) 166-170
6. Togni M., Windecker S., Cocchia R., et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 46 (2005) 231-236
7. Fuke S., Maekawa K., Kawamoto K., et al. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J 71 (2007) 220-225
8. Nabel E.G., Selwyn A.P., and Ganz P. Paradoxical narrowing of atherosclerotic coronary arteries induced by increases in heart rate. Circulation 81 (1990) 850-859
9. Prasad A., Husain S., and Quyyumi A. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition. A potential role of bradykinin. J Am Coll Cardiol 33 (1999) 796-804
10. Hanet C., Schroeder E., Michel X., et al. Flow-induced vasomotor response to tachycardia of the human internal mammary artery and saphenous vein grafts late following bypass surgery. Circulation 84 (1991) Suppl:III268-74
11. Hanet C., Evrard P., Jacquet L., Goenen M., and Robert A. Flow-mediated vasodilator response to tachycardia of epicardial coronary arteries is preserved in heart transplant recipients. Circulation 88 (1993) II257-II262
12. Grewe P.H., Deneke T., Machraoui A., Barmeyer J., and Muller K.M. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 35 (2006) 157-163
13. Maier W., Windecker S., Küng A., et al. Exercise-induced coronary artery vasodilation is not impaired by stent placement. Circulation 105 (2002) 2373-2377
14. Parry T.J., Brosius R., Thyagarajan R., et al. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol 524 (2005) 19-29
15. Steffel J., Latini R.A., Akhmedov A., et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 112 (2005) 2002-2011
16. Fukuda D., Sata M., Tanaka K., and Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 111 (2005) 926-931
17. Inoue T., Sata M., Hikichi Y., et al. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation 115 (2007) 553-561
18. Finn A.V., Kolodgie F.D., Harnek J., et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 (2005) 270-278
19. Finn A.V., Nakazawa G., Joner M., et al. Vascular responses to drug-eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27 (2007) 1500-1510
20. Finn A.V., Joner M., Nakazawa G., et al. Pathological correlates of late drug-eluting stent thrombosis. Strut coverage as a marker of endothelialization. Circulation 115 (2007) 2435-2441
21. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
22. Joner M., Finn A., Farb A., et al. Pathology of drug-eluting stents in humans. Delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
23. Luscher T.F., Steffel J., Eberli F.R., et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
24. Kotani J., Awata M., Nanto S., et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 47 (2006) 2108-2111
25. Matsumoto D., Shite J., Shinke T., et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J 28 (2007) 961-967
26. Ostojic M. Nobori Pharmacokinetics study. http://www.europcronline.com/fo/lecture Accessed November 19, 2007
27. Virmani R. Coronary drug-eluting stents: from animal studies to clinical practice. http://www.europcronline.com/fo/lecture Accessed November 19, 2007
28. Vetrovec G., Rizik D., Williard C., et al. Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions. Catheter Cardiovasc Interv 67 (2006) 32-37
29. Chevalier B., Serruys P.W., Silber S., et al. Randomized comparison of Nobori, Biolimus A9-eluting coronary stent with a Taxus, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: The Nobori 1 trial. Eurointerv 2 (2007) 426-434
30. Ostojic M., Sagic D., Beleslin B., et al. First clinical comparison of Nobori-Biolimus A9 drug eluting stent with Cypher-Sirolimus eluting stent: NOBORI CORE nine months and one year clinical outcomes. Eurointerv 3 (2008) 574-579
31. Schachinger V., Britten M.B., and Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000) 1899-1906